NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600™, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK) ("Circassia"), a specialty biopharmaceutical company focused on the allergy market.

The Agreement will provide Circassia with an exclusive license to use the device for allergy testing in the US market. Financial terms were not disclosed. The license complements an earlier agreement between the two companies, under which Circassia is using the device in its allergy immunotherapy clinical studies, and intends to provide the MicronJet600™ with its next generation treatments once approved.

Dr. Yotam Levin, Chief Executive of NanoPass, said, "We are delighted to expand our collaboration with our long term partner, Circassia, to the field of allergy testing. We see the significant potential to improve usability, accuracy and allergy patients' satisfaction by using this reliable device. Intradermal allergy testing is commonly used with certain allergens, such as bee venom and penicillin, and when skin prick tests are negative but the physician believes an allergy exists. Reliable intradermal delivery is critical for proper conduct and interpretation of this test, and performing it with a regular needle is typically difficult."

"This agreement executes NanoPass's strategy to expand its collaborations beyond vaccines into additional fields such as allergy and cancer, where intradermal (ID) delivery is enabling improved outcomes and diagnostics".